Retatrutide research in Canada investigates the multi-receptor agonism and metabolic signalling properties of this long-acting triple hormone receptor agonist. Retatrutide (LY3437943) is a synthetic fatty acid-conjugated peptide that simultaneously activates GLP-1 receptors, GIP receptors, and glucagon receptors, making it a triple agonist with a unique pharmacological profile. Canadian metabolic disease researchers study retatrutide to understand how simultaneous activation of three complementary hormone receptor systems affects weight regulation, glucose homeostasis, and lipid metabolism.
Triple Receptor Pharmacology Research
The three receptor systems each contribute differently to retatrutide’s metabolic effects. GLP-1R activation promotes insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite via central circuits. GIPR activation potentiates insulin secretion and may promote adipose tissue lipid mobilization. Glucagon receptor activation increases hepatic glucose output (counteracted by the GLP-1/GIP components) and increases energy expenditure via thermogenesis in brown adipose tissue. Canadian researchers study how these three signals integrate to produce metabolic outcomes.
Weight Loss Research Comparison
Retatrutide has shown substantially greater weight reduction in early clinical research compared to dual agonists (tirzepatide) and single GLP-1 agonists (semaglutide). Canadian researchers study retatrutide to understand whether the additional glucagon receptor component drives the incremental benefit through increased energy expenditure, enhanced lipolysis, or other mechanisms.
Sourcing Retatrutide in Canada
Research-grade retatrutide is available from EhBuddy Peptides in Canada. Lab-tested for purity. For laboratory research use only.
Retatrutide represents the current frontier of incretin-based metabolic receptor research in Canada, pushing the pharmacological toolkit beyond dual agonism into three-receptor biology.
